Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ASCO GU 2026: baseline Signatera positivity tracked with shorter recurrence-free survival in MIBC

In a 66-patient retrospective series presented at ASCO GU 2026, baseline Signatera ctDNA positivity before curative-intent treatment for urothelial carcinoma was associated with shorter recurrence-free survival (HR 5.15; 95% CI 1.41 to 18.78).

Journal of Clinical Oncology